IDXX vs ORKA stock comparison
IDEXX Laboratories vs. Oruka Therapeutics · data as of November 13, 2026
IDEXX Laboratories (IDXX) has a market value of about $55.5B, Oruka Therapeutics (ORKA) about $7.1B.
On our five checks IDEXX Laboratories scores higher: 3.4 out of 5 (good) against 0.4 (weak).
By area, the stronger company is IDEXX Laboratories on future growth; IDEXX Laboratories on track record; IDEXX Laboratories on financial health; IDEXX Laboratories on shareholder returns.
IDEXX Laboratories leads on 9 of the compared lines and Oruka Therapeutics on 1.
Side by side
| IDXX | ORKA | |
|---|---|---|
| Size and price | ||
| Market cap | $55.5B | $7.1B |
| Share price | $704.23 | $105.35 |
| Score | ||
| Overall score (of 5) | 3.4 | 0.4 |
| Value | 0 | 0 |
| Future growth | 4 | 0 |
| Track record | 5 | 0 |
| Financial health | 5 | 2 |
| Shareholder returns | 3 | 0 |
| Valuation | ||
| P/E (TTM) | 47.5 | — |
| Forward P/E | 44.8 | — |
| Price / free cash flow | 42.6 | — |
| Price / sales | 11.9 | — |
| EV / EBITDA | 33.5 | — |
| PEG | 3.32 | — |
| DCF value vs. price | −63% | — |
| Business | ||
| Revenue | $4.7B | — |
| Net income | $1.2B | -$105M |
| Free cash flow | $1.3B | -$88M |
| Net margin | 25.4% | — |
| Gross margin (5-yr avg.) | 60.2% | — |
| ROIC (5-yr avg.) | 44.1% | -22.8% |
| Growth | ||
| Revenue growth (1 yr) | 10.4% | — |
| Revenue growth (5 yrs, per year) | 9.7% | — |
| EPS growth (5 yrs, per year) | 14.3% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$301M | — |
| Dividend yield | None | None |
| Shareholder yield | 2.2% | 0.0% |
| Analysts | ||
| Upside to average target | +2% | +48% |
| Consensus rating | Buy | Strong buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: IDXX TTM to September 30, 2026, ORKA FY2025. Not investment advice.
Frequently asked questions
Which is the better stock, IDEXX Laboratories or Oruka Therapeutics?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) IDEXX Laboratories scores 3.4 out of 5 and Oruka Therapeutics 0.4; the table shows where each one is stronger.
Full IDEXX Laboratories analysis → Full Oruka Therapeutics analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.